In a rare moment of good news coming from the HSE, it has emerged today that the cost of the drug Fampyra will be borne by the health service.
Multiple Sclerosis patients have seen a dramatic improvement in their walking ability since the drug was introduced. Its downside, a price tag of up to €500.
The HSE has now reached an agreement with the drug’s manufacturer, Biogen Idec, to begin supplying the drug to those patients who greatly benefited from it.